Mendelian Randomization Study of Lipid Metabolites Reveals Causal Associations with Heel Bone Mineral Density

Background: Osteoporosis, which is a bone disease, is characterized by low bone mineral density and an increased risk of fractures. The heel bone mineral density is often used as a representative measure of overall bone mineral density. Lipid metabolism, which includes processes such as fatty acid metabolism, glycerol metabolism, inositol metabolism, bile acid metabolism, carnitine metabolism, ketone body metabolism, sterol and steroid metabolism, etc., may have an impact on changes in bone mineral density. While some studies have reported correlations between lipid metabolism and heel bone mineral density, the overall causal relationship between metabolites and heel bone mineral density remains unclear. Objective: to investigate the causal relationship between lipid metabolites and heel bone mineral density using two-sample Mendelian randomization analysis. Methods: Summary-level data from large-scale genome-wide association studies were extracted to identify genetic variants linked to lipid metabolite levels. These genetic variants were subsequently employed as instrumental variables in Mendelian randomization analysis to estimate the causal effects of each lipid metabolite on heel bone mineral density. Furthermore, metabolites that could potentially be influenced by causal relationships with bone mineral density were extracted from the KEGG and WikiPathways databases. The causal associations between these downstream metabolites and heel bone mineral density were then examined. Lastly, a sensitivity analysis was conducted to evaluate the robustness of the results and address potential sources of bias. Results: A total of 130 lipid metabolites were analyzed, and it was found that acetylcarnitine, propionylcarnitine, hexadecanedioate, tetradecanedioate, myo-inositol, 1-arachidonoylglycerophosphorine, 1-linoleoylglycerophoethanolamine, and epiandrosterone sulfate had a causal relationship with heel bone mineral density (p < 0.05). Furthermore, our findings also indicate an absence of causal association between the downstream metabolites associated with the aforementioned metabolites identified in the KEGG and WikiPathways databases and heel bone mineral density. Conclusion: This work supports the hypothesis that lipid metabolites have an impact on bone health through demonstrating a causal relationship between specific lipid metabolites and heel bone mineral density. This study has significant implications for the development of new strategies to osteoporosis prevention and treatment.

[1]  K. Wellen,et al.  Acetylcarnitine shuttling links mitochondrial metabolism to histone acetylation and lipogenesis , 2023, Science advances.

[2]  Shuhong Chen,et al.  Metabolome-Wide Mendelian Randomization Assessing the Causal Relationship Between Blood Metabolites and Bone Mineral Density , 2023, Calcified Tissue International.

[3]  H. Pan,et al.  Causal effect of polyunsaturated fatty acids on bone mineral density and fracture , 2022, Frontiers in Nutrition.

[4]  A. A. Abdel Rahman,et al.  Lipidomics Profiling of Patients with Low Bone Mineral Density (LBMD) , 2022, International journal of molecular sciences.

[5]  O. Shen,et al.  Association Between Human Blood Metabolome and the Risk of Psychiatric Disorders. , 2022, Schizophrenia bulletin.

[6]  S. Capuani,et al.  Behavior during aging of bone-marrow fatty-acids profile in women's calcaneus to search for early potential osteoporotic biomarkers: A 1H-MR spectroscopy study. , 2022, Bone.

[7]  Zeng-hui Zhao,et al.  Polyunsaturated Fatty Acids Level and Bone Mineral Density: A Two-Sample Mendelian Randomization Study , 2022, Frontiers in Endocrinology.

[8]  J. Mano,et al.  Endo- and Exometabolome Crosstalk in Mesenchymal Stem Cells Undergoing Osteogenic Differentiation , 2022, Cells.

[9]  Xiaoting Luo,et al.  UPLC/Q-TOF-MS-based Metabolomics Study of the Antiosteoporosis Effects of Vaccarin in Ovariectomized Mice , 2022, Planta Medica.

[10]  Li-juan Wang,et al.  Association between lipid biomarkers and osteoporosis: a cross-sectional study , 2020, BMC Musculoskeletal Disorders.

[11]  N. Sheehan,et al.  The use of two-sample methods for Mendelian randomization analyses on single large datasets , 2020, bioRxiv.

[12]  Yue Zhu,et al.  Mapping theme trends and recognizing hot spots in postmenopausal osteoporosis research: a bibliometric analysis , 2019, PeerJ.

[13]  Dhani Raj Chhetri,et al.  Myo-Inositol and Its Derivatives: Their Emerging Role in the Treatment of Human Diseases , 2019, Front. Pharmacol..

[14]  M. Fornage,et al.  A prospective study of serum metabolites and risk of ischemic stroke , 2019, Neurology.

[15]  R. Ventura,et al.  Sulfate metabolites improve retrospectivity after oral testosterone administration. , 2018, Drug testing and analysis.

[16]  Julian M. W. Quinn,et al.  An atlas of genetic influences on osteoporosis in humans and mice , 2018, Nature Genetics.

[17]  J. Ärnlöv,et al.  A Mendelian randomization study of the effects of blood lipids on breast cancer risk , 2018, Nature Communications.

[18]  Valeriia Haberland,et al.  The MR-Base platform supports systematic causal inference across the human phenome , 2018, eLife.

[19]  F. Müller,et al.  Biomarkers for In Vivo Assessment of Transporter Function , 2018, Pharmacological Reviews.

[20]  T. Spector,et al.  Metabolomic Pathways to Osteoporosis in Middle‐Aged Women: A Genome‐Metabolome‐Wide Mendelian Randomization Study , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  M. Thevis,et al.  Epiandrosterone sulfate prolongs the detectability of testosterone, 4-androstenedione, and dihydrotestosterone misuse by means of carbon isotope ratio mass spectrometry. , 2017, Drug testing and analysis.

[22]  S. Khosla,et al.  Osteoporosis treatment: recent developments and ongoing challenges. , 2017, The lancet. Diabetes & endocrinology.

[23]  Michael Jones,et al.  Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer , 2017, Nature Genetics.

[24]  S. Thompson,et al.  Interpreting findings from Mendelian randomization using the MR-Egger method , 2017, European Journal of Epidemiology.

[25]  Y. Miki,et al.  Phosphatidylethanolamine dynamics are required for osteoclast fusion , 2017, Scientific Reports.

[26]  Fernando Pires Hartwig,et al.  Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption , 2017, bioRxiv.

[27]  H. Schuppe,et al.  Role of steroid sulfatase in steroid homeostasis and characterization of the sulfated steroid pathway: Evidence from steroid sulfatase deficiency , 2016, Molecular and Cellular Endocrinology.

[28]  N. Sheehan,et al.  Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic , 2016, International journal of epidemiology.

[29]  A. Garber,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[30]  G. Davey Smith,et al.  Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator , 2016, Genetic epidemiology.

[31]  M. Bozzali,et al.  Bone Marrow Lipid Profiles from Peripheral Skeleton as Potential Biomarkers for Osteoporosis: A 1H-MR Spectroscopy Study. , 2016, Academic radiology.

[32]  Stephen Burgess,et al.  Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods , 2015, Statistics in medicine.

[33]  David M. Evans,et al.  Mendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality. , 2015, Annual review of genomics and human genetics.

[34]  G. Davey Smith,et al.  Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression , 2015, International journal of epidemiology.

[35]  N. Timpson,et al.  Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors , 2015, European Journal of Epidemiology.

[36]  I. Mohamed,et al.  A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality , 2014, Therapeutics and clinical risk management.

[37]  R. Willumeit,et al.  Phosphatidylethanolamine biomimetic coating increases mesenchymal stem cell osteoblastogenesis , 2014, Journal of Materials Science: Materials in Medicine.

[38]  John P. Overington,et al.  An atlas of genetic influences on human blood metabolites , 2014, Nature Genetics.

[39]  C. Gieger,et al.  Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism , 2014, European Journal of Epidemiology.

[40]  Anita Taylor,et al.  The Experience and Effectiveness of Nurse Practitioners in Orthopaedic Settings: A Comprehensive Systematic Review , 2012, JBI library of systematic reviews.

[41]  E. Lewiecki,et al.  Osteoporosis , 2011, Annals of Internal Medicine.

[42]  S. Thompson,et al.  Avoiding bias from weak instruments in Mendelian randomization studies. , 2011, International journal of epidemiology.

[43]  D. Miao,et al.  Sodium/myo‐inositol cotransporter 1 and myo‐inositol are essential for osteogenesis and bone formation , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  C. Hoppel,et al.  Mitochondria in the elderly: Is acetylcarnitine a rejuvenator? , 2009, Advanced drug delivery reviews.

[45]  E. Elm,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.

[46]  S. Pocock,et al.  Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, BMJ : British Medical Journal.

[47]  M. Haddaway,et al.  Bone loss after stroke over 52 weeks at os calcis: influence of sex, mobility and relation to bone density at other sites. , 2006, Age and ageing.

[48]  G. Mundy Nutritional modulators of bone remodeling during aging. , 2006, The American journal of clinical nutrition.

[49]  S. Chung,et al.  Sodium/myo‐inositol cotransporter‐1 is essential for the development and function of the peripheral nerves , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  D. Black,et al.  Clinical Practice. Postmenopausal Osteoporosis. , 2005, The New England journal of medicine.

[51]  R. E. Small,et al.  Uses and limitations of bone mineral density measurements in the management of osteoporosis. , 2005, MedGenMed : Medscape general medicine.

[52]  Robert Luben,et al.  Prediction of total and hip fracture risk in men and women by quantitative ultrasound of the calcaneus: EPIC-Norfolk prospective population study , 2004, The Lancet.

[53]  C C Glüer,et al.  Comparisons of Noninvasive Bone Mineral Measurements in Assessing Age‐Related Loss, Fracture Discrimination, and Diagnostic Classification , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[54]  C. Christiansen Osteoporosis: diagnosis and management today and tomorrow. , 1995, Bone.

[55]  M. Ito,et al.  Calcaneus as a site for assessment of bone mineral density: evaluation in cadavers and healthy volunteers. , 1993, AJR. American journal of roentgenology.

[56]  G. Berry,et al.  Kinetic evidence for compartmentalization of myo-inositol in hepatocytes. , 1993, Metabolism: clinical and experimental.

[57]  Claus Christiansen,et al.  Diagnosis of Osteoporosis , 1992, Southern medical journal.

[58]  G. Nelsestuen,et al.  Importance of phosphatidylethanolamine for association of protein kinase C and other cytoplasmic proteins with membranes. , 1992, Biochemistry.

[59]  J. Bremer,et al.  Propionylcarnitine. Physiological variations in vivo. , 1968, Biochimica et biophysica acta.

[60]  A. Khera,et al.  Mendelian Randomization. , 2017, JAMA.

[61]  S. Claypool,et al.  Phosphatidylethanolamine Metabolism in Health and Disease. , 2016, International review of cell and molecular biology.

[62]  L. Tosi,et al.  Fragility fractures: the fall and decline of bone health. Commentary on "Interventions to improve osteoporosis treatment following hip fracture" by Gardner et Al. , 2005, The Journal of bone and joint surgery. American volume.

[63]  P. Orozco Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women , 2004, European Journal of Epidemiology.

[64]  M. Giger,et al.  Normalized BMD as a predictor of bone strength. , 2000, Academic radiology.